Seribantumab is a monoclonal antibody commercialized by Elevation Oncology, with a leading Phase II program in Gallbladder Cancer. According to Globaldata, it is involved in 13 clinical trials, of which 9 were completed, 1 is ongoing, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Seribantumab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Seribantumab is expected to reach an annual total of $24 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Seribantumab (MM-121, SAR-256212) is under development for the treatment of NRG1 gene fusion positive solid tumors including pancreatic cancer, lung cancer, head and neck cancer, breast cancer, kidney cancer, colorectal cancer, bladder cancer, ovarian cancer, sarcoma, gallbladder cancer, bile duct cancer, esophageal cancer, uterine cancer and prostate cancer. The drug candidate is administered through intravenous route. MM-121 is a fully human IgG2 antibody that targets human epidermal growth factor receptor 3 (ErbB3 or EGFR3).
It was also under development for HER2 negative metastatic or triple negative breast cancer, platinum-resistant/refractory ovarian cancer, fallopian tube cancer, peritoneal cancer, endometrial cancer, squamous cell head and neck cancer (second line), non-small cell lung cancer, and epithelial ovarian cancer.
Elevation Oncology Overview
Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients. Elevation Oncology is headquartered in New York City, New York, the US.
The operating loss of the company was US$32.1 million in FY2021, compared to an operating loss of US$17.3 million in FY2020. The net loss of the company was US$32 million in FY2021, compared to a net loss of US$17.3 million in FY2020.
For a complete picture of Seribantumab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.